Exploring association between statin use and breast cancer risk: an updated meta-analysis

Archives of Gynecology and Obstetrics

Volumn 296, Issue 6, 2017, Pages 1043-1053

  Islam, Md Mohaimenul ^a   Yang, Hsuan Chia ^a   Nguyen, Phung Anh ^a   Poly, Tahmina Nasrin ^a   Huang, Chih Wei ^a   Kekade, Shwetambara ^a   Khalfan, Abdulwahed Mohammed ^b   Debnath, Tonmoy ^c   Li, Yu Chuan Jack ^a   Abdul, Shabbir Syed ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b PAAET ^*  (Kuwait)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Heterogeneity; Meta analysis; Relative risk; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN (PROTEIN); HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; DATA EXTRACTION; DRUG EXPOSURE; DRUG POTENCY; DRUG USE; HUMAN; META ANALYSIS; METHODOLOGY; PUBLISHING; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; STUDY DESIGN; TREATMENT DURATION; BREAST TUMOR; CHEMICALLY INDUCED; FEMALE; INCIDENCE; ODDS RATIO; RISK;

BREAST NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; ODDS RATIO; RISK;

EID: 85029741206     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-017-4533-3     Document Type: Review

References (67)

1. Eskitzis P, Zafrakas M, Papanicolaou A, Panagopoulou E, Gkoutzioulis M, Sympilidis G, Tarlatzis BC (2016) Quality-of-life changes over time in breast cancer patients undergoing breast-conserving surgery: a prospective study in Greece. Arch Gynecol Obstet 294(3):639–645
2. Matysiak M, Kapka-Skrzypczak L, Jodłowska-Jędrych B, Kruszewski M (2017) EMT promoting transcription factors as prognostic markers in human breast cancer. Arch Gynecol Obstet 295(4):817–825
3. Group HPSC (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. ACC Curr J Rev 11(6):34–35
4. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10–19
5. Gronich N, Rennert G (2013) Beyond aspirin [mdash] cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol 10(11):625–642
6. Undela K, Srikanth V, Bansal D (2012) Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 135(1):261–269
7. Wong WW, Dimitroulakos J, Minden M, Penn L (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16(4):508
8. Boudreau DM, Yu O, Johnson J (2010) Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9(4):603–621
9. DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18(1):54–61
10. Beck P, Wysowski DK, Downey W, Butler-Jones D (2003) Statin use and the risk of breast cancer. J Clin Epidemiol 56(3):280–285
11. Eaton M, Eklof J, Beal JR, Sahmoun AE (2009) Statins and breast cancer in postmenopausal women without hormone therapy. Anticancer Res 29(12):5143–5148
12. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S (2002) Statin use and the risk of breast and prostate cancer. Epidemiology 13(3):262–267
13. Cauley JA, Zmuda JM, Lui L-Y, Hillier TA, Ness RB, Stone KL, Cummings SR, Bauer DC (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Women’s Health 12(8):749–756
14. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM (2008) Statin use and risk of breast cancer. Cancer 112(1):27–33
15. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J (2010) Incidence of cancer and statin usage—record linkage study. Int J Cancer 126(1):279–284
16. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23(34):8606–8612
17. Baigent C, Keech A, Kearney P, Blackwell L (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366(9493):1267
18. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
19. Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions, vol 4. Wiley, New York
20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15):2008–2012
21. McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI (2013) Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age. Cancer Epidemiol Prev Biomark 22(9):1529–1537
22. Blais L, Desgagné A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the risk of cancer: a nested case–control study. Arch Intern Med 160(15):2363–2368
23. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR (2004) The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer 100(11):2308–2316
24. Leung HW, Chan AL, Lo D, Leung JH, Chen H-L (2013) Common cancer risk and statins: a population-based case–control study in a Chinese population. Expert Opin Drug Saf 12(1):19–27
25. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar H-J (2004) The risk of cancer in users of statins. J Clin Oncol 22(12):2388–2394
26. Kaye J, Jick H (2004) Statin use and cancer risk in the general practice research database. Br J Cancer 90(3):635–637
27. Leung HW, Hung L-L, Chan AL, Mou C-H (2015) Long-term use of antihypertensive agents and risk of breast cancer: a population-based case–control study. Cardiol Ther 4(1):65–76
28. Murakami R, Chen C, Lyu S-Y, Lin C-E, Tzeng P-C, Wang T-F, Chang J-C, Shieh Y-H, Chen I-F, Huang SK (2016) Lovastatin lowers the risk of breast cancer: a population-based study using logistic regression with a random effects model. SpringerPlus 5(1):1932
29. Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to statins and risk of common cancers: a series of nested case–control studies. BMC Cancer 11(1):409
30. Woditschka S, Habel LA, Udaltsova N, Friedman G, Sieh W (2010) Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Prev Biomark CEBP 0524:2010
31. Kochhar R, Khurana V, Bejjanki H, Caldito G, Fort C (2005) Statins to reduce breast cancer risk: a case control study in US female veterans. J Clin Oncol 23(16_suppl):514
32. Dumasia L, Lobocki C, Couturier A, Lebeis C, Drelichman A (2006) Use of statins and breast carcinoma: a case–control study. J Clin Oncol 24(18_suppl):592
33. Chan T-F, Wu C-H, Lin C-L, Yang C-Y (2014) Statin use and the risk of breast cancer: a population-based case–control study. Expert Opin Drug Saf 13(3):287–293
34. Borgquist S, Tamimi RM, Chen WY, Garber JE, Eliassen AH, Ahern TP (2016) Statin use and breast cancer risk in the nurses’ health study. Cancer Epidemiol Prev Biomark 25(1):201–206
35. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR (2007) Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Prev Biomark 16(3):416–421
36. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT (2006) Statin use and breast cancer: prospective results from the Women’s Health Initiative. J Natl Cancer Inst 98(10):700–707
37. Desai P, Chlebowski RT, Cauley JA, Manson JE, Wu C, Martin LW, Jay A, Bock CH, Cote ML, Petrucelli N (2013) Prospective analysis of association between statin use and breast cancer risk in the women’s health initiative. Cancer Epidemiol Prev Biomark CEBP 0562:2013
38. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2005) Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165(19):2264–2271
39. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sørensen HT, Olsen JH (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114(4):643–647
40. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Can Res 71(5):1763–1771
41. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S (2007) Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115(1):27–33
42. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67(1):99–109
43. Hague W, Forder P, Simes J, Hunt D, Tonkin A, Investigators L (2003) Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Am Heart J 145(4):643–651
44. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346):1623–1630
45. Hsia J, MacFadyen JG, Monyak J, Ridker PM (2011) Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol < 50 mg/dl with rosuvastatin: the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 57(16):1666–1675
46. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J, 4S Group n-f (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364(9436):771–777
47. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368(9542):1155–1163
48. Group HPSC (2005) The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 3(1):6
49. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335(14):1001–1009
50. Trial HA (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 288:2998–3007
51. Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, Stein EA, Langendorfer A, Beere PA, Gotto AM (2001) Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Women’s Health Gender-Based Med 10(10):971–981
52. Graaf M, Beiderbeck A, Egberts A, Richel D, Guchelaar H (2003) The risk of cancer in users of statins. Br J Clin Pharmacol 56(4):466–467
53. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon S-H, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148(1):244–258
54. Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011) Common cardiovascular medications in cancer therapeutics. Pharmacol Ther 130(2):177–190
55. Duncan RE, El-Sohemy A, Archer MC (2004) Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem 279(32):33079–33084
56. Gopalan A, Yu W, Sanders BG, Kline K (2013) Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Cancer Lett 329(1):9–16
57. Shi J, Liang D, Jin J, Wang L, He Y (2016) Female breast cancer burden was increasing during the 40 years in Hebei Province, China: a population-based study. Arch Gynecol Obstet 294(5):1063–1071
58. Yu H-L, Kolovos A, Christakos G, Chen J-C, Warmerdam S, Dev B (2007) Interactive spatiotemporal modelling of health systems: the SEKS–GUI framework. Stoch Env Res Risk Assess 21(5):555–572
59. Group HPSC (2002) Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in, 20, 536 high-risk individuals: a: randomised placebo-controlled trial. Lancet 360:7–22
60. Furberg CD, Wright JT, Davis BR, Cutler JA, Alderman M, Black H, Cushman W, Grimm R, Haywood LJ, Leenen F (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA J Am Med Assoc 288(23):2998–3007
61. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279(20):1615–1622
62. Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Choudhury GG (2010) Simvastatin induces derepression of PTEN expression via NFκB to inhibit breast cancer cell growth. Cell Signal 22(5):749–758
63. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C (2006) Breast cancer growth prevention by statins. Can Res 66(17):8707–8714
64. Islam MM, Iqbal U, Walther B, Atique S, Dubey N, Nguyen P-A, Poly T, Masud J, Li Y-C, Shabbir S-A (2016) Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology 47(3–4):181–191
65. Islam MM, Iqbal U, Walther BA, Nguyen P-A, Li Y-CJ, Dubey NK, Poly TN, Masud JHB, Atique S, Syed-Abdul S (2017) Gender-based personalized pharmacotherapy: a systematic review. Arch Gynecol Obstet 295(6):1305–1317
66. Yu L, Tan Y, Zhu L (2016) Dietary vitamin B2 intake and breast cancer risk: a systematic review and meta-analysis. Arch Gynecol Obstet 295(3):721–729
67. Schwab FD, Kilic N, Huang DJ, Schmid SM, Vetter M, Schötzau A, Güth U (2015) Personal or first-degree family breast cancer history: which has higher impact on tumor detection and tumor size in breast cancer. Arch Gynecol Obstet 291(6):1387–1394